BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine

MAINZ, GERMANY, and SHANGHAI, CHINA, January 25, 2021 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “Group”; Stock C

Latest News Clinical News 938
Read All

Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 25, 2021 -- Moderna Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced results from in vitr

Latest News Clinical News 855
Read All

Genentech’s Faricimab Meets Primary Endpoint in Two Global Phase III Studies and Shows Potential to Extend Time Between Treatments up to 16 Weeks for People With Neovascular Age-Related Macular Degeneration

South San Francisco, CA -- January 24, 2021 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from two identically designed global Phase I

Latest News Clinical News 702
Read All

Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19

NEW YORK & MAINZ, Germany--(BUSINESS WIRE) January 22, 2021 -- Pfizer and BioNTech SE today announced an advance purchase agreement with COVAX for up to 40 million doses of the Pfizer-BioNTech COV

Latest News Clinical News 667
Read All

Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine

GAITHERSBURG, Md., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announc

Latest News Clinical News 669
Read All

Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery

SAN DIEGO, Jan. 21, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatm

Latest News Clinical News 814
Read All

GSK Presents Positive Efficacy Data of Dostarlimab in Mismatch Repair-Deficient (dMMR) Solid Cancers at ASCO Gastrointestinal Cancers Symposium

London, UK -- 16 January 2021 -- GlaxoSmithKline (GSK) plc announced updated data from GARNET cohort F evaluating dostarlimab in mismatch repair-deficient (dMMR) non-endometrial advanced solid cancers

Latest News Clinical News 857
Read All

FDA Grants Fast Track Designation to Padeliporfin ImPACT for Steba Biotech

LUXEMBOURG, Jan. 17, 2021 /PRNewswire/ -- Steba biotech, pioneering developer of the IMmune Photo Activate Cancer Treatment (ImPACT), announced today that the U.S. Food and Drug Administration (FDA) h

Latest News Clinical News 688
Read All

Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture

New York and Mainz, Germany, January 20, 2021 -- Today, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from an in vitro study that provides additional data on the capability

Latest News Clinical News 754
Read All

Lilly's Neutralizing Antibody Bamlanivimab (LY-CoV555) Prevented COVID-19 at Nursing Homes in the BLAZE-2 Trial, Reducing Risk by up to 80 Percent for Residents

INDIANAPOLIS, Jan. 21, 2021 /PRNewswire/ -- Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lill

Latest News Clinical News 758
Read All

Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure

The Woodlands, Texas, January 14, 2021 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has received U.S. Food and Drug Administration (FDA) regulatory feedback that the results

Latest News Clinical News 732
Read All

Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in CDKL5 Deficiency Disorder (CDD)

RADNOR, Pa.--(BUSINESS WIRE) January 13, 2021 -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure di

Latest News Clinical News 1005
Read All
News
- CLINIEXPERT -
Int'l Clinical Service Expert

We are the leader
Because of our professionism